Clinical trial
Tamoxifen in the Prevention of Breast Cancer in Hodgkin's Disease Survivors
NCT00165308 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00165308 |
|---|---|
| Title | Tamoxifen in the Prevention of Breast Cancer in Hodgkin's Disease Survivors |
| Official title | A Feasibility Study of Tamoxifen Prevention of Breast Cancer in Hodgkin's Disease Survivors |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Brigham and Women's Hospital Massachusetts General Hospital AstraZeneca Industry |
| Status | Completed |
| Study type | Interventional |
| Conditions | Hodgkin's Disease, Breast Cancer |
| Intervention type | Drug |
| Interventions | Tamoxifen |
| Enrollment | 29 |
| Start date | Apr 1, 2001 |
| Primary completion | Mar 1, 2004 |
| Completion | Jun 1, 2009 |
| First posted | Sep 14, 2005 |
| Last update posted | Jul 9, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: